Whalesbook
Dekho dosto, India mein na diabetes aur BP jaise metabolic disorders bahut tezi se badh rahe hain. Yeh pharma companies ke liye ek dum zabardast market hai, jo 2032 tak $145.09 billion tak jaane wala hai. Lagbhag 75 million Indians 2025 tak diabetes se suffer kar sakte hain.
Isi mauke ko dekhte hue, Dr. Reddy's Laboratories bhi is field mein apna stake badhana chahti hai. Company ka market cap waise toh ₹1.03 lakh crore ($12.4 billion USD) hai aur trailing P/E 18.7 chal raha hai. Pichhle saal stock 5% bhaga tha, par 2026 mein abhi tak 3% neeche bhi aaya hai, jiska bhav ₹1230-₹1235 ke beech tha April mein.
Lekin bhai, yeh race aasan nahi hai. India mein Sun Pharma aur Cipla jaise bade khiladi pehle se hain. Aur sabse badi problem hai - affordability. Kya joh advanced treatments Dr. Reddy's la rahi hai, woh aam janta afford kar paayegi? Yeh sawal sabse bada hai.
Uske upar se, company ko kuch regulatory issues ka saamna bhi karna pad raha hai. Jaise unki semaglutide wali dawai Brazil mein reject ho gayi aur Canada mein abhi approval ka wait hai. Yeh semaglutide unke future plans ke liye kaafi important hai. Yeh sab issues dekh kar hi global brokerage Citi ne stock par 'Sell' rating di hai.
Morgan Stanley ne bhi FY25-26 ke liye earnings estimates thode kam kar diye hain, aur keh rahe hain ki GLP-1 therapies ko lekar abhi clarity nahi hai. Pichhle saal ka 5% ka gain, is saal ke 3% ke loss mein badal gaya hai, jo market sentiment ko dikhata hai.
Aur haan, Russian tax authorities ne bhi April 2026 mein ₹1.14 crore ka penalty lagaya tha. Matlab, mauka bada hai, par mushkilein bhi kum nahi.
Analysts overall 'Hold' rating de rahe hain, aur FY28 tak earnings mein sudhar ki umeed hai, par woh tabhi hoga jab yeh sab hurdles clear honge.